Patents by Inventor Craig Erickson

Craig Erickson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20230414611
    Abstract: Identification of Fragile X syndrome (FXS) patients who are likely to respond to a treatment involving a GABAA receptor modulator (e.g., a selective GABAA receptor stimulator), for example, at a low dose, using peripheral Fragile X mental retardation protein (FMRP) as a biomarker, either taken alone or in combination with other biomarkers. Also provided here are methods for treating such FXS patients using the GABAA receptor modulator (e.g., a selective GABAA receptor stimulator at a low dose).
    Type: Application
    Filed: November 12, 2021
    Publication date: December 28, 2023
    Applicant: CHILDREN'S HOSPITAL MEDICAL CENTER
    Inventors: Craig A. ERICKSON, Christina GROSS, Ernest PEDAPATI, Lauren SCHMITT
  • Publication number: 20230295654
    Abstract: Methods for alleviating symptoms in a Fragile X Syndrome (FXS) patient using adeno-associated viral (AAV) 9 viral particles encoding a wild-type human fragile X mental retardation 1 (FMR1) protein (human FMRP). Also provided herein are methods to determine suitable doses of AAV9 viral particles for a FXS patient to alleviate at least one symptom associated with FXS, as well as methods for monitoring treatment efficacy.
    Type: Application
    Filed: July 16, 2021
    Publication date: September 21, 2023
    Applicants: CHILDREN'S HOSPITAL MEDICAL CENTER, FORGE BIOLOGICS, INC.
    Inventors: Ernest PEDAPATI, Christina GROSS, Craig ERICKSON, David DISMUKE, Erandi Kanchana DE SILVA
  • Patent number: 11733243
    Abstract: Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitor patients treated with acamprosate and to screen potentially therapeutic compounds.
    Type: Grant
    Filed: March 13, 2020
    Date of Patent: August 22, 2023
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Craig Erickson, Debomoy Lahiri
  • Patent number: 11535160
    Abstract: A safety rail system for a flatbed. The system is portable, installs and dismantles in minutes, and is adaptable to any flatbed trailer or truck having post mounting side pockets. The system collapses into a compact package for stowing and transport. The system utilizes existing post mounting side pockets to establish a fence line that supports one or more cable rails. The cable(s) of the cable rails are drawn taut to provide a firm barrier to protect equipment and personnel from falling off the edge of the flatbed.
    Type: Grant
    Filed: June 20, 2019
    Date of Patent: December 27, 2022
    Assignee: Safety Rail Company, LLC
    Inventor: Craig Erickson
  • Publication number: 20220249483
    Abstract: Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.
    Type: Application
    Filed: March 17, 2022
    Publication date: August 11, 2022
    Inventors: Craig Erickson, Tori Lynn Schaefer
  • Patent number: 11311539
    Abstract: Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.
    Type: Grant
    Filed: December 5, 2019
    Date of Patent: April 26, 2022
    Assignee: Children's Hospital Medical Center
    Inventors: Craig Erickson, Tori Lynn Schaefer
  • Patent number: 11254468
    Abstract: A pallet system for shipping and storage of railing segments. The pallet system captures the corners of a plurality of railing segments, thereby diminishing the weight, footprint, and materials of construction requirements. In some embodiments, a plurality of the pallet systems can be stacked. The diminished size of the pallet system components after removal of the railing segments can be returned to the shipper in a refund exchange arrangement. In some embodiments, the plurality of railing segments is maintained in a fixed relationship using a spacer that is inserted laterally through the plurality of railing segments.
    Type: Grant
    Filed: June 29, 2020
    Date of Patent: February 22, 2022
    Assignee: Safety Rail Company, LLC
    Inventor: Craig Erickson
  • Publication number: 20200360316
    Abstract: The invention provides a method for treating a medical condition in a patient, the method comprising: administering to a patient in need (thereof a pharmaceutical composition comprising a therapeutically effective amount of (i) a first therapeutic agent which is acamprosate or a pharmaceutically acceptable salt thereof and (ii) a second therapeutic agent which is D-cycloserine, a salt of D-cycloserine, an ester of D-cycloserine, an alkylated D-cycloserine, or a precursor of D-cycloserine.
    Type: Application
    Filed: June 2, 2020
    Publication date: November 19, 2020
    Inventors: Steven L. JOHNS, Craig A. ERICKSON
  • Publication number: 20200225233
    Abstract: Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitor patients treated with acamprosate and to screen potentially therapeutic compounds.
    Type: Application
    Filed: March 13, 2020
    Publication date: July 16, 2020
    Applicant: Indiana University Research and Technology Corporation
    Inventors: Craig Erickson, Debomoy Lahiri
  • Patent number: 10634677
    Abstract: Studies in mouse models of Fragile X and preliminary studies in human youth demonstrate that ERK1/2 is biomarker useful to monitoring the treatment of people diagnosed with ASD. Results reported herein demonstrate that acamprosate has the ability to reduce levels of ERK1/2 activation associated with many of the symptoms of ASD. Accordingly, in addition to its utility as a diagnostic marker for ASD ERK1/2 activation levels can be used to monitory patients treated with acamprosate.
    Type: Grant
    Filed: October 14, 2014
    Date of Patent: April 28, 2020
    Assignee: Indiana University Research and Technology Corporation
    Inventors: Craig Erickson, Debomoy Lahiri
  • Publication number: 20200121682
    Abstract: Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.
    Type: Application
    Filed: December 5, 2019
    Publication date: April 23, 2020
    Inventors: Craig Erickson, Tori Lynn Schaefer
  • Patent number: 10588905
    Abstract: Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.
    Type: Grant
    Filed: November 19, 2018
    Date of Patent: March 17, 2020
    Assignee: Children's Hospital Medical Center
    Inventors: Craig Erickson, Tori Lynn Schaefer
  • Publication number: 20190389387
    Abstract: A safety rail system for a flatbed. The system is portable, installs and dismantles in minutes, and is adaptable to any flatbed trailer or truck having post mounting side pockets. The system collapses into a compact package for stowing and transport. The system utilizes existing post mounting side pockets to establish a fence line that supports one or more cable rails. The cable(s) of the cable rails are drawn taut to provide a firm barrier to protect equipment and personnel from falling off the edge of the flatbed.
    Type: Application
    Filed: June 20, 2019
    Publication date: December 26, 2019
    Inventor: Craig Erickson
  • Publication number: 20190083493
    Abstract: Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.
    Type: Application
    Filed: November 19, 2018
    Publication date: March 21, 2019
    Inventors: Craig Erickson, Tori Lynn Schaefer
  • Patent number: 10159673
    Abstract: Disclosed are methods of alleviating or preventing one or more symptoms associated with fragile X syndrome in an individual in need thereof via administration of a therapeutically effective amount of a GABA(A) alpha 2 and/or 3 partial agonist. The one or more symptoms may include impaired functional communication, anxiety, inattention, hyperactivity, sensory reactivity, autonomic nervous system dysregulation, aberrant eye gaze, self-injury, aggression, seizures, EEG abnormalities, including but not limited to, abnormal spectral analysis, event related potentials which may include auditory and visual responses, abnormalities in cortical responses as evoked by transcranial magnetic stimulation including resting and active motor thresholds and abnormal responses in measures of cortical inhibition and excitation, aberrant impaired cognitive function, compromised daily living skills, or a combination thereof.
    Type: Grant
    Filed: November 21, 2017
    Date of Patent: December 25, 2018
    Assignee: Children's Hospital Medical Center
    Inventors: Craig Erickson, Tori Lynn Schaefer
  • Patent number: D896236
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: September 15, 2020
    Assignee: Magic Leap, Inc.
    Inventors: Paul Armistead Hoover, James M. Powderly, Lorena Pazmino, Gregory Minh Tran, Jonathan Lawrence Mann, Craig Erickson, Savannah Niles, Alysha Naples, Isioma Osagbemwenorue Azu, Cole Parker Heiner
  • Patent number: D910707
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: February 16, 2021
    Assignee: Magic Leap, Inc.
    Inventors: Lorena Pazmino, Sarah Machicado, James M. Powderly, Karen Stolzenberg, Cole Parker Heiner, Isioma Osagbemwenorue Azu, Brian Everett Meaney, Megan Ann Geiman, Tim Zurmoehle, Andrea Isabel Montoya, Gregory Minh Tran, Amy Dedonato, William Wheeler, Kenneth Kian Ann Tay, Craig Erickson, Jonathan Lawrence Mann, Jonathan David Garn, Daryl Francis Tanghe, William Adams, Ian Michener Bradley
  • Patent number: D918232
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: May 4, 2021
    Assignee: Magic Leap, Inc.
    Inventors: Paul Armistead Hoover, James M. Powderly, Lorena Pazmino, Gregory Minh Tran, Jonathan Lawrence Mann, Craig Erickson, Savannah Niles, Alysha Naples, Isioma Osagbemwenorue Azu, Cole Parker Heiner
  • Patent number: D920992
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: June 1, 2021
    Assignee: Magic Leap, Inc.
    Inventors: Lorena Pazmino, James M. Powderly, Karen Stolzenberg, Cole Parker Heiner, Isioma Osagbemwenorue Azu, Tim Zurmoehle, Andrea Isabel Montoya, Gregory Minh Tran, Amy Dedonato, Craig Erickson, Jonathan Lawrence Mann, Spencer Davis
  • Patent number: D928809
    Type: Grant
    Filed: August 17, 2020
    Date of Patent: August 24, 2021
    Assignee: Magic Leap, Inc.
    Inventors: Paul Armistead Hoover, James M. Powderly, Lorena Pazmino, Gregory Minh Tran, Jonathan Lawrence Mann, Craig Erickson, Savannah Niles, Alysha Naples, Isioma Osagbemwenorue Azu, Cole Parker Heiner